A woman who used Wegovy and Ozempic says the drugmaker didn't adequately warn her, or other patients, of serious side effects ...

Share on Pinterest A new study found no link between semaglutide use and suicidal ideation while another recent study showed the inverse. Halfpoint Images/Getty Images The authors of a new study ...

A new study finds a significant correlation between the use of semaglutide drugs such as Ozempic, antidepressant, or benzodiazepine use, and suicidal ideation. No such link was found between ...

Weight loss drugs made with so-called GLP-1 analogs like semaglutide—including Ozempic, Wegovy and Mounjaro—were not found to be associated with an increased risk of depression, suicidal ...

A study published in JAMA Internal Medicine finds semaglutide, a weight loss medication, does not increase depressive symptoms or suicidal behavior in individuals without known mental health disorders ...

3, 2024 (HealthDay News) -- The booming popularity of the weight-loss drug semaglutide has prompted increasing concerns about potential side effects from taking Ozempic or Wegovy. But a new study ...

But the Australian missionary, who has become a naturalised PNG citizen because of the decades he spent doing missionary work in PNG, would not back down. At a meeting for the church clergy in East ...

It found that, while taking semaglutide once a weekly did not reduce rates of COVID-19 overall, it led to fewer “COVID-19 related adverse events.” Placebo-takers recorded a 3.1% occurrence, while ...

So it is with semaglutide, sold under the brand names Ozempic and Wegovy, which was developed to treat diabetes and then found to be an effective weight-loss treatment. The latest research reports ...

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without ...

Semaglutide, better known as Ozempic, "has far-reaching benefits beyond what we initially imagined," Prof Harlan Krumholz, from the Yale School of Medicine, said following the publication of ...